These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1906658)

  • 1. In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a.
    de Riese W; Allhoff E; Stief CG; Lenis G; Schlick R; Liedke S; Anton P; Jonas U
    Urol Res; 1991; 19(2):87-90. PubMed ID: 1906658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
    Sella A; Logothetis CJ; Fitz K; Dexeus FH; Amato R; Kilbourn R; Wallace S
    J Urol; 1992 Mar; 147(3):573-7. PubMed ID: 1538431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay.
    Homma Y; Aso Y
    Eur Urol; 1994; 25(2):164-70. PubMed ID: 8137859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.
    Küpeli S; Beksac M; Küpeli B; Baltaci S; Süzer O
    Int Urol Nephrol; 1997; 29(4):421-6. PubMed ID: 9405998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer.
    Kellokumpu-Lehtinen P; Nordman E
    Cancer Detect Prev; 1988; 12(1-6):523-9. PubMed ID: 3180144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy--a pilot study.
    Kröger MJ; Menzel T; Gschwend JE; Bergmann L
    Anticancer Res; 1999; 19(2C):1553-5. PubMed ID: 10365144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer.
    Schuster D; Schneider G; Ade N; Heim ME
    Onkologie; 1990 Oct; 13(5):359-62. PubMed ID: 2082231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma.
    Fosså SD; de Garis ST; Heier MS; Flokkmann A; Lien HH; Salveson A; Moe B
    Cancer; 1986 Apr; 57(8 Suppl):1700-4. PubMed ID: 3948141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro drug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b.
    Küpeli B; Baltaci S; Beksac M; Süzer O; Küpeli S; Göğüs O
    Int Urol Nephrol; 1997; 29(1):79-84. PubMed ID: 9203042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reactive proteins in renal cell carcinoma patients treated by IFN alpha alone or in combination with vinblastine.
    Juranić Z; Stanojević-Bakić N; Maletić V; Borkovacki R
    Neoplasma; 1994; 41(4):229-32. PubMed ID: 7935998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Our experience with interferon alpha: renal cell carcinoma.
    Merimsky O; Chaitchik S
    Mol Biother; 1992 Sep; 4(3):130-4. PubMed ID: 1445666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma.
    Rizzo M; Bartoletti R; Selli C; Sicignano A; Criscuolo D
    Eur Urol; 1989; 16(4):271-7. PubMed ID: 2670581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine.
    Papadopoulos I; Rudolph P; Weichert-Jacobsen K; Thiemann O; Papadopoulou D
    Urology; 1996 Sep; 48(3):373-8. PubMed ID: 8804488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.
    Schornagel JH; Verweij J; ten Bokkel Huinink WW; Klijn JG; de Mulder PH; Debruyne FM; van Deijk WA; Roozendaal K; Kok TC; Veenhof KH
    J Urol; 1989 Aug; 142(2 Pt 1):253-6. PubMed ID: 2746739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon-alpha therapy in hypernephroma].
    Sagaster KP
    Wien Med Wochenschr; 1993; 143(16-17):443-7. PubMed ID: 8273370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.